Contents

Search

clodronate; clodronic acid (Clodronsaeure, Clasteon, Bonefos, Loron)

1st generation bisphosphonate not available in USA. Indications: - adjunctive to androgen-deprivation therapy in men with metastatic prostate cancer Dosage: 2080 mg PO QD Mechanism of action:

Interactions

drug adverse effects of bisphosphonates

General

bisphosphonate

Database Correlations

PUBCHEM correlations

References

  1. Dearnaley DP et al Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: Long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol 2009 Sep; 10:872 http://dx.doi.org/10.1016/S1470-2045(09)70201-3
  2. Dearnaley DP et al A Double-Blind, Placebo-Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial) Journal of the National Cancer Institute 2003 95(17):1300-1311 doi:10.1093/jnci/djg038 http://dx.doi.org/10.1136/bmj.b2477
  3. Mason MD et al Oral sodium clodronate for nonmetastatic prostate cancer - Results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst 2007 May 16; 99:765-76. PMID: 17505072